Turtle Creek Wealth Advisors LLC Sells 2,320 Shares of Intuitive Surgical, Inc. $ISRG

Posted by Brenda Bartman on Oct 15th, 2026

Turtle Creek Wealth Advisors LLC decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG – Free Report) by 28.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 5,926 shares of the medical equipment provider’s stock after selling 2,320 shares during the period. Turtle Creek Wealth Advisors LLC’s holdings in Intuitive Surgical were worth $2,410,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in ISRG. Invesco Ltd. boosted its position in Intuitive Surgical by 17.4% during the 4th quarter. Invesco Ltd. now owns 4,128,735 shares of the medical equipment provider’s stock valued at $2,338,350,000 after buying an additional 611,268 shares during the period. Bank of America Corp DE increased its holdings in Intuitive Surgical by 3.3% during the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider’s stock valued at $1,667,388,000 after purchasing an additional 116,292 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of Intuitive Surgical in the 2nd quarter worth approximately $1,335,753,000. J. Stern & Co. LLP raised its holdings in shares of Intuitive Surgical by 18,504.6% during the fourth quarter. J. Stern & Co. LLP now owns 2,127,248 shares of the medical equipment provider’s stock valued at $1,204,788,000 after acquiring an additional 2,115,814 shares in the last quarter. Finally, Amundi boosted its holdings in Intuitive Surgical by 8.6% in the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider’s stock valued at $1,119,448,000 after acquiring an additional 193,096 shares in the last quarter. Institutional investors own 83.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on ISRG shares. Stifel Nicolaus dropped their target price on shares of Intuitive Surgical from $670.00 to $550.00 and set a “buy” rating for the company in a research report on Friday, July 17th. Robert W. Baird lowered their target price on Intuitive Surgical from $525.00 to $500.00 and set an “outperform” rating for the company in a research note on Friday, July 17th. Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a report on Friday, August 14th. UBS Group reiterated a “buy” rating on shares of Intuitive Surgical in a research note on Tuesday. Finally, BNP Paribas Exane raised shares of Intuitive Surgical to an “outperform” rating in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $498.83.

Check Out Our Latest Stock Analysis on Intuitive Surgical

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, Director Amy L. Ladd sold 72 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $393.10, for a total value of $28,303.20. Following the transaction, the director directly owned 179 shares of the company’s stock, valued at approximately $70,364.90. This trade represents a 28.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $375.57, for a total transaction of $28,918.89. Following the completion of the transaction, the executive vice president directly owned 881 shares in the company, valued at approximately $330,877.17. The trade was a 8.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock valued at $4,891,989 over the last three months. 0.60% of the stock is owned by insiders.

Intuitive Surgical Price Performance

NASDAQ ISRG traded up $6.19 during mid-day trading on Thursday, reaching $426.43. The stock had a trading volume of 859,235 shares, compared to its average volume of 2,402,024. Intuitive Surgical, Inc. has a 1 year low of $328.57 and a 1 year high of $603.88. The stock has a market cap of $150.65 billion, a PE ratio of 48.80, a price-to-earnings-growth ratio of 3.18 and a beta of 1.46. The company has a fifty day moving average price of $389.39 and a 200 day moving average price of $409.80.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last posted its quarterly earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.48 by $0.32. The firm had revenue of $2.89 billion during the quarter, compared to analysts’ expectations of $2.83 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company’s revenue was up 18.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.81 earnings per share. As a group, equities research analysts expect that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

Intuitive Surgical Company Profile

(Free Report)

Intuitive Surgical, Inc develops and commercializes robotic-assisted systems and related technologies designed to support minimally invasive medical procedures. The company’s products are intended to help surgeons perform operations through small incisions while providing enhanced visualization, precision, and control.

Its principal product is the da Vinci Surgical System, a platform used across a range of specialties, including general surgery, urology, gynecology, thoracic surgery, and cardiac procedures.